Loading stock data…
$1.07+0.02 (+1.42%)
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.
Annovis Bio, Inc. in the Healthcare sector is trading at $1.04 with a market capitalization of $51M. Wall Street consensus targets $10.50 (4 analysts), implying a +904.8% move over the next 12 months. The stock is currently near its 52-week low of $1.01, remaining 49.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$14.38M↑ | -$18.01M↓ | -$9.71M↓ | -$7.43M↓ | -$6.27M |
| Net Income | -$14.82M↑ | -$17.61M↓ | -$9.83M↓ | -$7.26M↓ | -$6.22M |
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label ...